Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-08

AUTHORS

M.J.A. de Jonge, J.P. Droz, L. Paz-Ares, A.T. van Oosterom, R. de Wit, P. Chollet, B. Baron, D. Lacombe, K. Mettinger, P. Fumoleau

ABSTRACT

OBJECTIVE: To investigate the antitumor activity and the safety of RFS2000, an oral topoisomerase I inhibitor, in patients with advanced or metastatic urothelial tract tumors refractory to one prior chemotherapy regimen. PATIENTS AND METHODS: Eligible patients were to have failed first line treatment for advanced or metastatic disease. Patients received RFS2000 as one daily oral intake at the dose of 1.5 mg/m(2)/day according to a "5 days on/2 days" off schedule continuously. One cycle was arbitrarily defined as a 3 week period. Sufficient oral fluid intake to prevent cystitis previously described in phase I trials with RFS2000 was recommended. Gehan design was used for sample size determination. Anti-tumor activity was evaluated according to the RECIST criteria and toxicity according to CTC version 2. RESULTS: Twenty patients received a total of 57 cycles (range 1-8). Grade 3-4 toxicity was observed in 10 patients requiring dose or schedule modifications. Hematological grade 3-4 toxicity was observed in 16% of the cycles. Only one patient experienced a partial response. CONCLUSIONS: RFS2000 could be administered orally as a "5 days on/2 days off" schedule continuously with a median dose intensity of 90.6% with an acceptable toxicity profile. However, RFS2000 did not exert significant activity in patients with advanced/metastatic urothelial tract tumors failing prior chemotherapy. The results of this study do not suggest further investigation of RFS2000 at the present dose and schedule for the treatment of urothelial tract tumors in this refractory population. More... »

PAGES

329-333

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/b:drug.0000026260.24275.02

DOI

http://dx.doi.org/10.1023/b:drug.0000026260.24275.02

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1051459422

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15122081


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Camptothecin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Topoisomerase I Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urologic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urothelium", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Daniel den Hoed Cancer Center/Erasmus Medical Center, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Jonge", 
        "givenName": "M.J.A.", 
        "id": "sg:person.0624326131.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624326131.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Droz", 
        "givenName": "J.P.", 
        "id": "sg:person.01100247112.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100247112.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitario 12 De Octubre", 
          "id": "https://www.grid.ac/institutes/grid.144756.5", 
          "name": [
            "Hospital Universito 12 de Octubre, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paz-Ares", 
        "givenName": "L.", 
        "id": "sg:person.0751054024.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751054024.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universitaire Ziekenhuizen Leuven", 
          "id": "https://www.grid.ac/institutes/grid.410569.f", 
          "name": [
            "U.Z. Gasthuisberg, Leuven, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Oosterom", 
        "givenName": "A.T.", 
        "id": "sg:person.0653245357.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653245357.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Daniel den Hoed Cancer Center/Erasmus Medical Center, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Wit", 
        "givenName": "R.", 
        "id": "sg:person.0701764263.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701764263.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Jean Perrin", 
          "id": "https://www.grid.ac/institutes/grid.418113.e", 
          "name": [
            "Centre Jean Perrin, Clermont-Ferrand, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chollet", 
        "givenName": "P.", 
        "id": "sg:person.010365661254.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010365661254.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "European Organisation for Research and Treatment of Cancer", 
          "id": "https://www.grid.ac/institutes/grid.418936.1", 
          "name": [
            "EORTC DataCenter, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baron", 
        "givenName": "B.", 
        "id": "sg:person.0647660275.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647660275.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "European Organisation for Research and Treatment of Cancer", 
          "id": "https://www.grid.ac/institutes/grid.418936.1", 
          "name": [
            "EORTC DataCenter, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lacombe", 
        "givenName": "D.", 
        "id": "sg:person.0734641722.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734641722.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "SuperGen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.430719.8", 
          "name": [
            "SuperGen, Inc., Dublin, CA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mettinger", 
        "givenName": "K.", 
        "id": "sg:person.0723335041.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723335041.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut de Canc\u00e9rologie de l'Ouest", 
          "id": "https://www.grid.ac/institutes/grid.418191.4", 
          "name": [
            "Centre Ren\u00e9 Gauducheau, Nantes-St Herblain, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fumoleau", 
        "givenName": "P.", 
        "id": "sg:person.01101667531.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101667531.56"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/00001813-199801000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003376363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-199801000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003376363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-199801000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003376363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1997.106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006224843", 
          "https://doi.org/10.1038/bjc.1997.106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1997.106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006224843", 
          "https://doi.org/10.1038/bjc.1997.106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(02)00070-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007858719"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002800100360", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009595448", 
          "https://doi.org/10.1007/s002800100360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/canjclin.49.1.33", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012951033"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(02)00022-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024681219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1997.491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048065376", 
          "https://doi.org/10.1038/bjc.1997.491"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1997.491", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048065376", 
          "https://doi.org/10.1038/bjc.1997.491"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1005860806635", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052702047", 
          "https://doi.org/10.1023/a:1005860806635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.20.4.937", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064202828"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.17.3068", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074702294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.10.2638", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074814007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1992.10.7.1066", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077093351"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077116355", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(17)42494-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079695765"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(17)48996-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1080095427"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082608533", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082755070", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.5.1853", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083094765"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-08", 
    "datePublishedReg": "2004-08-01", 
    "description": "OBJECTIVE: To investigate the antitumor activity and the safety of RFS2000, an oral topoisomerase I inhibitor, in patients with advanced or metastatic urothelial tract tumors refractory to one prior chemotherapy regimen.\nPATIENTS AND METHODS: Eligible patients were to have failed first line treatment for advanced or metastatic disease. Patients received RFS2000 as one daily oral intake at the dose of 1.5 mg/m(2)/day according to a \"5 days on/2 days\" off schedule continuously. One cycle was arbitrarily defined as a 3 week period. Sufficient oral fluid intake to prevent cystitis previously described in phase I trials with RFS2000 was recommended. Gehan design was used for sample size determination. Anti-tumor activity was evaluated according to the RECIST criteria and toxicity according to CTC version 2.\nRESULTS: Twenty patients received a total of 57 cycles (range 1-8). Grade 3-4 toxicity was observed in 10 patients requiring dose or schedule modifications. Hematological grade 3-4 toxicity was observed in 16% of the cycles. Only one patient experienced a partial response.\nCONCLUSIONS: RFS2000 could be administered orally as a \"5 days on/2 days off\" schedule continuously with a median dose intensity of 90.6% with an acceptable toxicity profile. However, RFS2000 did not exert significant activity in patients with advanced/metastatic urothelial tract tumors failing prior chemotherapy. The results of this study do not suggest further investigation of RFS2000 at the present dose and schedule for the treatment of urothelial tract tumors in this refractory population.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1023/b:drug.0000026260.24275.02", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "22"
      }
    ], 
    "name": "Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors", 
    "pagination": "329-333", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f5218063f8ad2c694684bdabaa6df63f06ec6760711b4f6e0cb4205cc2fa06a3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15122081"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/b:drug.0000026260.24275.02"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1051459422"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/b:drug.0000026260.24275.02", 
      "https://app.dimensions.ai/details/publication/pub.1051459422"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8663_00000491.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1023/B:DRUG.0000026260.24275.02"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/b:drug.0000026260.24275.02'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/b:drug.0000026260.24275.02'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/b:drug.0000026260.24275.02'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/b:drug.0000026260.24275.02'


 

This table displays all metadata directly associated to this object as RDF triples.

273 TRIPLES      21 PREDICATES      63 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/b:drug.0000026260.24275.02 schema:about N01fb72aa28524eaeaed2ab279096637c
2 N03a7374a06de4d7b86806f74f9723e8a
3 N0926e29c98714b92a4a24595d3c6240c
4 N1253c52db8b5426393a4beb9ad507d73
5 N22ba4b7d73794d6abeab635283160f07
6 N39ba0bdef3ce41e8a9a16fbeeab75100
7 N4794a85041af40039bf84a4b526921d0
8 N47ad9f9fc8644f12915dd3dd20f047dd
9 N95cf808e2ee5420c81a1f69f1fca3f92
10 N9d5b1fc5fae442a9bc2686745ec39fd3
11 Nc736cd6fbe5445e787d06dcb67b15d71
12 Nc7435820b799451087692e3e4c70f57f
13 Ncdb49715dbee444a9f0c68e176e61c47
14 Ndba366947c714094b7ec60e818bfc087
15 Ne83b9bd0f2c1427880718d3868cc27bb
16 Nf14a1017c53a4e0e8fe0c06e01faf849
17 anzsrc-for:11
18 anzsrc-for:1115
19 schema:author N80229b01c06c499cbd65bc536c2f1820
20 schema:citation sg:pub.10.1007/s002800100360
21 sg:pub.10.1023/a:1005860806635
22 sg:pub.10.1038/bjc.1997.106
23 sg:pub.10.1038/bjc.1997.491
24 https://app.dimensions.ai/details/publication/pub.1077116355
25 https://app.dimensions.ai/details/publication/pub.1082608533
26 https://app.dimensions.ai/details/publication/pub.1082755070
27 https://doi.org/10.1016/s0022-5347(17)42494-3
28 https://doi.org/10.1016/s0022-5347(17)48996-8
29 https://doi.org/10.1016/s0959-8049(02)00022-9
30 https://doi.org/10.1016/s0959-8049(02)00070-9
31 https://doi.org/10.1097/00001813-199801000-00004
32 https://doi.org/10.1200/jco.1992.10.7.1066
33 https://doi.org/10.1200/jco.1997.15.5.1853
34 https://doi.org/10.1200/jco.20.4.937
35 https://doi.org/10.1200/jco.2000.18.17.3068
36 https://doi.org/10.1200/jco.2001.19.10.2638
37 https://doi.org/10.3322/canjclin.49.1.33
38 schema:datePublished 2004-08
39 schema:datePublishedReg 2004-08-01
40 schema:description OBJECTIVE: To investigate the antitumor activity and the safety of RFS2000, an oral topoisomerase I inhibitor, in patients with advanced or metastatic urothelial tract tumors refractory to one prior chemotherapy regimen. PATIENTS AND METHODS: Eligible patients were to have failed first line treatment for advanced or metastatic disease. Patients received RFS2000 as one daily oral intake at the dose of 1.5 mg/m(2)/day according to a "5 days on/2 days" off schedule continuously. One cycle was arbitrarily defined as a 3 week period. Sufficient oral fluid intake to prevent cystitis previously described in phase I trials with RFS2000 was recommended. Gehan design was used for sample size determination. Anti-tumor activity was evaluated according to the RECIST criteria and toxicity according to CTC version 2. RESULTS: Twenty patients received a total of 57 cycles (range 1-8). Grade 3-4 toxicity was observed in 10 patients requiring dose or schedule modifications. Hematological grade 3-4 toxicity was observed in 16% of the cycles. Only one patient experienced a partial response. CONCLUSIONS: RFS2000 could be administered orally as a "5 days on/2 days off" schedule continuously with a median dose intensity of 90.6% with an acceptable toxicity profile. However, RFS2000 did not exert significant activity in patients with advanced/metastatic urothelial tract tumors failing prior chemotherapy. The results of this study do not suggest further investigation of RFS2000 at the present dose and schedule for the treatment of urothelial tract tumors in this refractory population.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree false
44 schema:isPartOf N62d0a84399c64a7689446822f4cf27fd
45 N7ed34428439b42f8b87ceef7fe81470b
46 sg:journal.1094201
47 schema:name Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors
48 schema:pagination 329-333
49 schema:productId N0a860d8f10da48c7947a2327d8377123
50 N1c80534c62224cde9c27d894dba05845
51 N3705a2988dba418a9fc4801fa9173a97
52 N821a3e4a4bf34d70872d90f46a385cf7
53 Ne2b33ae479e143658b32810e3c9c77c7
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051459422
55 https://doi.org/10.1023/b:drug.0000026260.24275.02
56 schema:sdDatePublished 2019-04-10T14:56
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher Nabb5fdf907e04da1bd7725d9451295c9
59 schema:url http://link.springer.com/10.1023/B:DRUG.0000026260.24275.02
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N01fb72aa28524eaeaed2ab279096637c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Neoplasm Metastasis
65 rdf:type schema:DefinedTerm
66 N03a7374a06de4d7b86806f74f9723e8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Antineoplastic Agents
68 rdf:type schema:DefinedTerm
69 N03bbcd24660846e1a8fe7ec65940c46a schema:name Daniel den Hoed Cancer Center/Erasmus Medical Center, Rotterdam, The Netherlands
70 rdf:type schema:Organization
71 N0926e29c98714b92a4a24595d3c6240c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Urologic Neoplasms
73 rdf:type schema:DefinedTerm
74 N0a860d8f10da48c7947a2327d8377123 schema:name readcube_id
75 schema:value f5218063f8ad2c694684bdabaa6df63f06ec6760711b4f6e0cb4205cc2fa06a3
76 rdf:type schema:PropertyValue
77 N0c3a9b52c8d9421cba5e4c1b637f9084 rdf:first sg:person.0653245357.14
78 rdf:rest Ned84600a1238461fb5114b2e2735a303
79 N1253c52db8b5426393a4beb9ad507d73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Administration, Oral
81 rdf:type schema:DefinedTerm
82 N1649adacbd7344b0a5b669f3d56e260c rdf:first sg:person.0647660275.36
83 rdf:rest Na30c9cb95b8f4382a0cea01fc43bae65
84 N1bf9628ccaed4086b6cd59a2b6c3b6f4 rdf:first sg:person.01101667531.56
85 rdf:rest rdf:nil
86 N1c80534c62224cde9c27d894dba05845 schema:name nlm_unique_id
87 schema:value 8309330
88 rdf:type schema:PropertyValue
89 N22ba4b7d73794d6abeab635283160f07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Treatment Outcome
91 rdf:type schema:DefinedTerm
92 N2f4780b236fd42f8902e1111eb557b35 rdf:first sg:person.01100247112.66
93 rdf:rest N9f5dfa9e78164d27bdd29674633a8bfa
94 N3705a2988dba418a9fc4801fa9173a97 schema:name doi
95 schema:value 10.1023/b:drug.0000026260.24275.02
96 rdf:type schema:PropertyValue
97 N39ba0bdef3ce41e8a9a16fbeeab75100 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Adult
99 rdf:type schema:DefinedTerm
100 N4794a85041af40039bf84a4b526921d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Drug Administration Schedule
102 rdf:type schema:DefinedTerm
103 N47ad9f9fc8644f12915dd3dd20f047dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Topoisomerase I Inhibitors
105 rdf:type schema:DefinedTerm
106 N62d0a84399c64a7689446822f4cf27fd schema:issueNumber 3
107 rdf:type schema:PublicationIssue
108 N644ce06e2e7d4dffbb7614262c899df4 rdf:first sg:person.010365661254.35
109 rdf:rest N1649adacbd7344b0a5b669f3d56e260c
110 N7cf333913a5a449681621cccc4dcb711 schema:name Daniel den Hoed Cancer Center/Erasmus Medical Center, Rotterdam, The Netherlands
111 rdf:type schema:Organization
112 N7ed34428439b42f8b87ceef7fe81470b schema:volumeNumber 22
113 rdf:type schema:PublicationVolume
114 N80229b01c06c499cbd65bc536c2f1820 rdf:first sg:person.0624326131.96
115 rdf:rest N2f4780b236fd42f8902e1111eb557b35
116 N821a3e4a4bf34d70872d90f46a385cf7 schema:name dimensions_id
117 schema:value pub.1051459422
118 rdf:type schema:PropertyValue
119 N95cf808e2ee5420c81a1f69f1fca3f92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Urothelium
121 rdf:type schema:DefinedTerm
122 N9d5b1fc5fae442a9bc2686745ec39fd3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Camptothecin
124 rdf:type schema:DefinedTerm
125 N9f5dfa9e78164d27bdd29674633a8bfa rdf:first sg:person.0751054024.47
126 rdf:rest N0c3a9b52c8d9421cba5e4c1b637f9084
127 Na30c9cb95b8f4382a0cea01fc43bae65 rdf:first sg:person.0734641722.53
128 rdf:rest Ne79ad74111a54a80a84951c6effc9a6a
129 Nabb5fdf907e04da1bd7725d9451295c9 schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 Nc736cd6fbe5445e787d06dcb67b15d71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Aged
133 rdf:type schema:DefinedTerm
134 Nc7435820b799451087692e3e4c70f57f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Neoplasm Recurrence, Local
136 rdf:type schema:DefinedTerm
137 Ncdb49715dbee444a9f0c68e176e61c47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Male
139 rdf:type schema:DefinedTerm
140 Ndba366947c714094b7ec60e818bfc087 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Female
142 rdf:type schema:DefinedTerm
143 Ne2b33ae479e143658b32810e3c9c77c7 schema:name pubmed_id
144 schema:value 15122081
145 rdf:type schema:PropertyValue
146 Ne79ad74111a54a80a84951c6effc9a6a rdf:first sg:person.0723335041.12
147 rdf:rest N1bf9628ccaed4086b6cd59a2b6c3b6f4
148 Ne83b9bd0f2c1427880718d3868cc27bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Middle Aged
150 rdf:type schema:DefinedTerm
151 Ned84600a1238461fb5114b2e2735a303 rdf:first sg:person.0701764263.64
152 rdf:rest N644ce06e2e7d4dffbb7614262c899df4
153 Nf14a1017c53a4e0e8fe0c06e01faf849 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Humans
155 rdf:type schema:DefinedTerm
156 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
157 schema:name Medical and Health Sciences
158 rdf:type schema:DefinedTerm
159 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
160 schema:name Pharmacology and Pharmaceutical Sciences
161 rdf:type schema:DefinedTerm
162 sg:journal.1094201 schema:issn 0167-6997
163 1573-0646
164 schema:name Investigational New Drugs
165 rdf:type schema:Periodical
166 sg:person.010365661254.35 schema:affiliation https://www.grid.ac/institutes/grid.418113.e
167 schema:familyName Chollet
168 schema:givenName P.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010365661254.35
170 rdf:type schema:Person
171 sg:person.01100247112.66 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
172 schema:familyName Droz
173 schema:givenName J.P.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100247112.66
175 rdf:type schema:Person
176 sg:person.01101667531.56 schema:affiliation https://www.grid.ac/institutes/grid.418191.4
177 schema:familyName Fumoleau
178 schema:givenName P.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101667531.56
180 rdf:type schema:Person
181 sg:person.0624326131.96 schema:affiliation N03bbcd24660846e1a8fe7ec65940c46a
182 schema:familyName de Jonge
183 schema:givenName M.J.A.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624326131.96
185 rdf:type schema:Person
186 sg:person.0647660275.36 schema:affiliation https://www.grid.ac/institutes/grid.418936.1
187 schema:familyName Baron
188 schema:givenName B.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647660275.36
190 rdf:type schema:Person
191 sg:person.0653245357.14 schema:affiliation https://www.grid.ac/institutes/grid.410569.f
192 schema:familyName van Oosterom
193 schema:givenName A.T.
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653245357.14
195 rdf:type schema:Person
196 sg:person.0701764263.64 schema:affiliation N7cf333913a5a449681621cccc4dcb711
197 schema:familyName de Wit
198 schema:givenName R.
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701764263.64
200 rdf:type schema:Person
201 sg:person.0723335041.12 schema:affiliation https://www.grid.ac/institutes/grid.430719.8
202 schema:familyName Mettinger
203 schema:givenName K.
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723335041.12
205 rdf:type schema:Person
206 sg:person.0734641722.53 schema:affiliation https://www.grid.ac/institutes/grid.418936.1
207 schema:familyName Lacombe
208 schema:givenName D.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734641722.53
210 rdf:type schema:Person
211 sg:person.0751054024.47 schema:affiliation https://www.grid.ac/institutes/grid.144756.5
212 schema:familyName Paz-Ares
213 schema:givenName L.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751054024.47
215 rdf:type schema:Person
216 sg:pub.10.1007/s002800100360 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009595448
217 https://doi.org/10.1007/s002800100360
218 rdf:type schema:CreativeWork
219 sg:pub.10.1023/a:1005860806635 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052702047
220 https://doi.org/10.1023/a:1005860806635
221 rdf:type schema:CreativeWork
222 sg:pub.10.1038/bjc.1997.106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006224843
223 https://doi.org/10.1038/bjc.1997.106
224 rdf:type schema:CreativeWork
225 sg:pub.10.1038/bjc.1997.491 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048065376
226 https://doi.org/10.1038/bjc.1997.491
227 rdf:type schema:CreativeWork
228 https://app.dimensions.ai/details/publication/pub.1077116355 schema:CreativeWork
229 https://app.dimensions.ai/details/publication/pub.1082608533 schema:CreativeWork
230 https://app.dimensions.ai/details/publication/pub.1082755070 schema:CreativeWork
231 https://doi.org/10.1016/s0022-5347(17)42494-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079695765
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1016/s0022-5347(17)48996-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1080095427
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1016/s0959-8049(02)00022-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024681219
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1016/s0959-8049(02)00070-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007858719
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1097/00001813-199801000-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003376363
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1200/jco.1992.10.7.1066 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077093351
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1200/jco.1997.15.5.1853 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083094765
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1200/jco.20.4.937 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064202828
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1200/jco.2000.18.17.3068 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074702294
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1200/jco.2001.19.10.2638 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074814007
250 rdf:type schema:CreativeWork
251 https://doi.org/10.3322/canjclin.49.1.33 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012951033
252 rdf:type schema:CreativeWork
253 https://www.grid.ac/institutes/grid.144756.5 schema:alternateName Hospital Universitario 12 De Octubre
254 schema:name Hospital Universito 12 de Octubre, Madrid, Spain
255 rdf:type schema:Organization
256 https://www.grid.ac/institutes/grid.410569.f schema:alternateName Universitaire Ziekenhuizen Leuven
257 schema:name U.Z. Gasthuisberg, Leuven, Belgium
258 rdf:type schema:Organization
259 https://www.grid.ac/institutes/grid.418113.e schema:alternateName Centre Jean Perrin
260 schema:name Centre Jean Perrin, Clermont-Ferrand, France
261 rdf:type schema:Organization
262 https://www.grid.ac/institutes/grid.418116.b schema:alternateName Centre Léon Bérard
263 schema:name Centre Léon Bérard, Lyon, France
264 rdf:type schema:Organization
265 https://www.grid.ac/institutes/grid.418191.4 schema:alternateName Institut de Cancérologie de l'Ouest
266 schema:name Centre René Gauducheau, Nantes-St Herblain, France
267 rdf:type schema:Organization
268 https://www.grid.ac/institutes/grid.418936.1 schema:alternateName European Organisation for Research and Treatment of Cancer
269 schema:name EORTC DataCenter, Brussels, Belgium
270 rdf:type schema:Organization
271 https://www.grid.ac/institutes/grid.430719.8 schema:alternateName SuperGen (United States)
272 schema:name SuperGen, Inc., Dublin, CA
273 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...